Comparison of the on‐treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis

Ha, Ingyoon; Chung, Jung Wha; Jang, Eun Sun; Jeong, Sook Hyang; Kim, Jin‐Wook

doi:10.1111/jgh.15031

Cited by 23 publications

(32 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, elastographic reversion of cirrhosis after 5 years of follow-up was more prevalent after tenofovir compared to entecavir. Another retrospective cohort study [56] in 1340 consecutive NA-naïve CHB patients reported a similar risk for HCC development after entecavir and tenofovir treatment.…”

Section: Risk Of Hcc Development In Chronic Hbv-infected Patients Tre...mentioning

confidence: 84%

Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg)

Kaur

Talat

Karimi‐Sari

et al. 2022

JCM

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related death worldwide. Hepatitis B virus (HBV) infection is among the main risk factors for HCC. The risk of HCC is not eliminated completely after viral suppression, due to HBV DNA integrated into human chromosomes. Cirrhosis, HBV viral DNA levels, age, male gender, the immune response of the host against HBV, and a combination of obesity and diabetes are among the main risk factors for HCC. Active viral replication and long-standing active disease with inflammation are associated with a higher risk of HCC. Treatment of HBV with nucleos(t)ide analogues (NAs) decreased HCC risk by effectively decreasing viral load and inflammation. Similar risk factors have been reported in hepatitis B patients after seroclearance. Studies have reported decreased risk of HCC after seroclearance, but there were also conflicting results from a few studies indicating no difference in risk of developing HCC. The difference in HCC rates could be because of other factors such as coinfection, occult HBV infection, family history, HBV genotype, and other comorbidities. Due to the persistent risk of HCC after seroclearance, HCC surveillance is critical for early detection, especially in high-risk patients. However, long-term studies might be needed to further validate the results.

show abstract

Section: Risk Of Hcc Development In Chronic Hbv-infected Patients Tre...mentioning

confidence: 84%

Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg)

Kaur

Talat

Karimi‐Sari

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Of particular note is that the score was predictive of HCC even among subjects with low viral load. Therefore, it can be helpful in stratifying residual HCC risk for the majority of today's patients on antiviral therapy with a high barrier to resistance, 33,34 despite further studies are warranted.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, it can be helpful in stratifying residual HCC risk for the majority of today's patients on antiviral therapy with a high barrier to resistance, 33,34 despite further studies are warranted.…”

Section: Mediation Analysismentioning

confidence: 99%

Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B‐related hepatocellular carcinoma

Huang

Tsai

Hsu

et al. 2020

Molecular Carcinogenesis

View full text Add to dashboard Cite

Despite considerable knowledge of viral pathogenesis, the pathophysiological changes related to the multifactorial, multistep process of hepatitis B virus (HBV)related hepatocellular carcinoma (HCC) development remains unclear. Longitudinal metabolomics study can reveal biological process for disease progression. We performed metabolite profiling with longitudinal prediagnostic plasma samples from two nested case-control studies of hepatitis B surface antigen carriers participating in ultrasound screening for HCC, one within a government employee cohort (870 samples from 109 HCC cases and 107 controls) and the other within a hospitalbased cohort (266 samples from 63 HCC cases and 114 controls). Of the 34 measured metabolites, tyrosine, isoleucine, and glutamine were consistently associated with HCC. In analyses combining longitudinal data, a high metabolic risk score based on the three amino acids was robustly associated with increased risk of HCC (OR = 3.71, 95% confidence interval: 2.53-5.42), even after adjustment for clinical factors, or when assessed for different times up to ≥8 years before diagnosis.

show abstract

“…A single-center retrospective cohort study from Korea analyzed 1,340 patients, and showed that HCC risk was statistically similar between ETV and TDF groups, either by PSM (aHR, 2.06; 95% CIs, 0.98–4.33; P =0.058) or IPTW (aHR, 1.30; 95% CIs, 0.81–2.10; P =0.276) [ 14 ].…”

Section: Entecavir and Tenofovir Equally Prevents Hccmentioning

confidence: 99%

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

et al. 2021

View full text Add to dashboard Cite

Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development. a Data are presented as mean ± standard deviation. 4060 (100) 6145 (100) 16.9 18.1 49 (0.61) 41 (0.32)

show abstract

Comparison of the on‐treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis

Cited by 23 publications

References 49 publications

Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg)

Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg)

Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B‐related hepatocellular carcinoma

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Contact Info

Product

Resources

About